AmerisourceBergen Implements New SEC Rule for Internet Posting of Proxy Materials
Company Provides Details on 2008 Annual Meeting of Stockholders
VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jan. 21, 2008--AmerisourceBergen (NYSE:ABC) today began mailing its "Notice of Internet Availability of Proxy Materials" for its 2008 Annual Meeting of Stockholders under the new Notice and Access rule of the U.S. Securities and Exchange Commission (SEC).
AmerisourceBergen is among the first large accelerated filers to implement the SEC's new Notice and Access rule. The rule allows companies to furnish proxy materials to stockholders via the Internet as an alternative to the traditional approach of delivering a printed set to each stockholder. The proxy statement for the 2008 annual meeting, stockholder letter and the 2007 Annual Report on Form 10-K as filed with the SEC for the fiscal year ended September 30, 2007 are available on the 2008 Proxy Materials page in the Investor Relations section of www.amerisourcebergen.com. AmerisourceBergen stockholders also may obtain hard copies of the Company's proxy materials for the 2008 annual meeting free of charge by following the instructions provided in the "Notice of Internet Availability of Proxy Materials" that was mailed to stockholders on or about January 18, 2008.
The Company's Annual Meeting of Stockholders will be held on February 28, 2008 at 2:00 pm Eastern Time at The Four Seasons Hotel in Philadelphia, Pennsylvania.
AmerisourceBergen is one of the world's largest pharmaceutical services companies serving primarily the United States and Canada. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $66 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 11,500 people. AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes (including increased government regulation of the pharmaceutical supply channel); government enforcement initiatives (including (i) the imposition of increased obligations upon pharmaceutical distributors to detect and prevent suspicious orders of controlled substances, (ii) the commencement of further administrative actions by the U. S. Drug Enforcement Administration seeking to suspend or revoke the license of any of the Company's distribution facilities to distribute controlled substances, (iii) the commencement of any enforcement actions by any U.S. Attorney alleging violation of laws and regulations regarding diversion of controlled substances and suspicious order monitoring, or (iv) the commencement of any administrative actions by the board of pharmacy of any state seeking to suspend, revoke or otherwise restrict the ability of any of the Company's distribution facilities or businesses to distribute or dispense pharmaceuticals in such state); changes in U.S. government policies (including reimbursement changes arising from federal legislation, including the Medicare Modernization Act and the Deficit Reduction Act of 2005); changes in regulatory or clinical medical guidelines and/or reimbursement practices for the pharmaceuticals we distribute, including erythropoiesis-stimulating agents (ESAs) used to treat anemia patients; price inflation in branded pharmaceuticals and price deflation in generics; the inability of the Company to successfully complete any transaction that the Company may wish to pursue from time to time; fluctuations in market interest rates; operational or control issues arising from the Company's outsourcing of information technology activities; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar - Canadian dollar exchange rate and other foreign exchange rates; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; any operating problems and/or cost overruns that may be associated with the implementation of an enterprise resource planning system; changes in tax legislation or adverse resolution of challenges to our tax positions; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the business of the Company generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2007 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.
Michael N. Kilpatric, 610-727-7118